(19)
(11) EP 1 171 078 A2

(12)

(88) Date of publication A3:
25.01.2001

(43) Date of publication:
16.01.2002 Bulletin 2002/03

(21) Application number: 00918362.5

(22) Date of filing: 24.03.2000
(51) International Patent Classification (IPC)7: A61K 6/00
(86) International application number:
PCT/US0007/870
(87) International publication number:
WO 0057/837 (05.10.2000 Gazette 2000/40)
(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 26.03.1999 US 277401

(71) Applicants:
  • Aventis Pharmaceuticals Inc.
    Bridgewater, NJ 08807-0800 (US)
  • THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Philadelphia, Pennsylvania 19104-3246 (US)

(72) Inventors:
  • JAYE, Michael
    Glenside, PA 19038 (US)
  • LYNCH, Kevin, J.
    Landsdale, PA 19446 (US)
  • AMIN, Dilip, V.
    Lansdale, PA 19446 (US)
  • DOAN, Kim-Anh, Thi
    Spring City, PA 19475 (US)
  • MARCHADIER, Dawn
    Voorhees, NJ 08043 (US)
  • MAUGEAIS, Cyrille
    Philadelphia, PA 19102 (US)
  • RADER, Daniel, J.
    Philadelphia, PA 19146 (US)
  • KRAWIEC, John, A.
    Gulph Mills, PA 19406 (US)
  • SOUTH, Victoria, J.
    Collegeville, PA 19426 (US)

(74) Representative: Jones, Stephen Anthony et al
AdamsonJones Broadway Business Centre 32a Stoney Street
Nottingham NG1 1LL
Nottingham NG1 1LL (GB)

   


(54) COMPOSITIONS AND METHODS FOR EFFECTING THE LEVELS OF HIGH DENSITY LIPOPROTEIN (HDL) CHOLESTEROL AND APOLIPOPROTEIN AI, VERY LOW DENSITY LIPOPROTEIN (VLDL) CHOLESTEROL AND LOW DENSITY LIPOPROTEIN (LDL) CHOLESTEROL